Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review

Saad M. Ibrahim, Robert J. Lewandowski, Kent T. Sato, Vanessa L. Gates, Laura Kulik, Mary F. Mulcahy, Robert K. Ryu, Reed A. Omary, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalReview article

76 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. The majority of patients with HCC present with unresectable disease. These patients have historically had limited treatment options secondary to HCC demonstrating chemoresistance to the currently available systemic therapies. Additionally, normal liver parenchyma has shown intolerance to tumoricidal radiation doses, limiting the use of external beam radiation. Because of these limitations, novel percutaneous liver-directed therapies have emerged. The targeted infusion of radioactive microspheres (radioembolization) represents one such therapy. Radioembolization is a minimally invasive transcatheter therapy through which radioactive microspheres are infused into the hepatic arteries that supply tumor. Once infused, these microspheres traverse the hepatic vascular plexus and selectively implant within the tumor arterioles. Embedded within the arterioles, the 90Y impregnated microspheres emit high energy and low penetrating radiation doses selectively to the tumor. Radioembolization has recently shown promise for the treatment of patients with unresectable HCC. The objective of this review article is to highlight two currently available radioembolic devices (90Y, 188Rh) and provide the reader with a recent review of the literature.

Original languageEnglish (US)
Pages (from-to)1664-1669
Number of pages6
JournalWorld Journal of Gastroenterology
Volume14
Issue number11
DOIs
StatePublished - Mar 21 2008

Fingerprint

Hepatocellular Carcinoma
Microspheres
Arterioles
Radiation
Liver
Neoplasms
Therapeutics
Hepatic Artery
Blood Vessels
Equipment and Supplies

Keywords

  • Brachytherapy
  • Hepato-cellular carcinoma
  • Radioembolization
  • Rhenium-188
  • Yttrium-90

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{c3f8236ad2074042b82523ea132928c8,
title = "Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review",
abstract = "Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. The majority of patients with HCC present with unresectable disease. These patients have historically had limited treatment options secondary to HCC demonstrating chemoresistance to the currently available systemic therapies. Additionally, normal liver parenchyma has shown intolerance to tumoricidal radiation doses, limiting the use of external beam radiation. Because of these limitations, novel percutaneous liver-directed therapies have emerged. The targeted infusion of radioactive microspheres (radioembolization) represents one such therapy. Radioembolization is a minimally invasive transcatheter therapy through which radioactive microspheres are infused into the hepatic arteries that supply tumor. Once infused, these microspheres traverse the hepatic vascular plexus and selectively implant within the tumor arterioles. Embedded within the arterioles, the 90Y impregnated microspheres emit high energy and low penetrating radiation doses selectively to the tumor. Radioembolization has recently shown promise for the treatment of patients with unresectable HCC. The objective of this review article is to highlight two currently available radioembolic devices (90Y, 188Rh) and provide the reader with a recent review of the literature.",
keywords = "Brachytherapy, Hepato-cellular carcinoma, Radioembolization, Rhenium-188, Yttrium-90",
author = "Ibrahim, {Saad M.} and Lewandowski, {Robert J.} and Sato, {Kent T.} and Gates, {Vanessa L.} and Laura Kulik and Mulcahy, {Mary F.} and Ryu, {Robert K.} and Omary, {Reed A.} and Riad Salem",
year = "2008",
month = "3",
day = "21",
doi = "10.3748/wjg.14.1664",
language = "English (US)",
volume = "14",
pages = "1664--1669",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "11",

}

Radioembolization for the treatment of unresectable hepatocellular carcinoma : A clinical review. / Ibrahim, Saad M.; Lewandowski, Robert J.; Sato, Kent T.; Gates, Vanessa L.; Kulik, Laura; Mulcahy, Mary F.; Ryu, Robert K.; Omary, Reed A.; Salem, Riad.

In: World Journal of Gastroenterology, Vol. 14, No. 11, 21.03.2008, p. 1664-1669.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radioembolization for the treatment of unresectable hepatocellular carcinoma

T2 - A clinical review

AU - Ibrahim, Saad M.

AU - Lewandowski, Robert J.

AU - Sato, Kent T.

AU - Gates, Vanessa L.

AU - Kulik, Laura

AU - Mulcahy, Mary F.

AU - Ryu, Robert K.

AU - Omary, Reed A.

AU - Salem, Riad

PY - 2008/3/21

Y1 - 2008/3/21

N2 - Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. The majority of patients with HCC present with unresectable disease. These patients have historically had limited treatment options secondary to HCC demonstrating chemoresistance to the currently available systemic therapies. Additionally, normal liver parenchyma has shown intolerance to tumoricidal radiation doses, limiting the use of external beam radiation. Because of these limitations, novel percutaneous liver-directed therapies have emerged. The targeted infusion of radioactive microspheres (radioembolization) represents one such therapy. Radioembolization is a minimally invasive transcatheter therapy through which radioactive microspheres are infused into the hepatic arteries that supply tumor. Once infused, these microspheres traverse the hepatic vascular plexus and selectively implant within the tumor arterioles. Embedded within the arterioles, the 90Y impregnated microspheres emit high energy and low penetrating radiation doses selectively to the tumor. Radioembolization has recently shown promise for the treatment of patients with unresectable HCC. The objective of this review article is to highlight two currently available radioembolic devices (90Y, 188Rh) and provide the reader with a recent review of the literature.

AB - Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. The majority of patients with HCC present with unresectable disease. These patients have historically had limited treatment options secondary to HCC demonstrating chemoresistance to the currently available systemic therapies. Additionally, normal liver parenchyma has shown intolerance to tumoricidal radiation doses, limiting the use of external beam radiation. Because of these limitations, novel percutaneous liver-directed therapies have emerged. The targeted infusion of radioactive microspheres (radioembolization) represents one such therapy. Radioembolization is a minimally invasive transcatheter therapy through which radioactive microspheres are infused into the hepatic arteries that supply tumor. Once infused, these microspheres traverse the hepatic vascular plexus and selectively implant within the tumor arterioles. Embedded within the arterioles, the 90Y impregnated microspheres emit high energy and low penetrating radiation doses selectively to the tumor. Radioembolization has recently shown promise for the treatment of patients with unresectable HCC. The objective of this review article is to highlight two currently available radioembolic devices (90Y, 188Rh) and provide the reader with a recent review of the literature.

KW - Brachytherapy

KW - Hepato-cellular carcinoma

KW - Radioembolization

KW - Rhenium-188

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=41849089345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849089345&partnerID=8YFLogxK

U2 - 10.3748/wjg.14.1664

DO - 10.3748/wjg.14.1664

M3 - Review article

C2 - 18350597

AN - SCOPUS:41849089345

VL - 14

SP - 1664

EP - 1669

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 11

ER -